Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma

Acta Neuropathologica Communications

Volumn 2, Issue 1, 2014, Pages

  Ida, Cristiane M ^a   Vrana, Julie A ^a   Rodriguez, Fausto J ^b   Jentoft, Mark E ^a   Caron, Alissa A ^a   Jenkins, Sarah M ^a   Giannini, Caterina ^a  

^a MAYO CLINIC   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRAF V600E; Immunohistochemistry; Pleomorphic xanthoastrocytoma

Indexed keywords

EID: 85005929942     PISSN: None     EISSN: 20515960     Source Type: Journal    
DOI: 10.1186/2051-5960-1-20     Document Type: Article

References (39)

1. Emuss V, Garnett M, Mason C, Marais R: Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res 2005, 65: 9719-9726. 10.1158/0008-5472.CAN-05-1683
2. Niault TS, Baccarini M: Targets of Raf in tumorigenesis. Carcinogenesis 2010, 31: 1165-1174. 10.1093/carcin/bgp337
3. Wellbrock C, Karasarides M, Marais R: The RAF proteins take centre stage. Nat Rev Mol Cell Biol 2004, 5: 875-885. 10.1038/nrm1498
4. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al.: Mutations of the BRAF gene in human cancer. Nature 2002, 417: 949-954. 10.1038/nature00766
5. Basto D, Trovisco V, Lopes JM, Martins A, Pardal F, Soares P, Reis RM: Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathol 2005, 109: 207-210. 10.1007/s00401-004-0936-x
6. Jeuken J, van den Broecke C, Gijsen S, Boots-Sprenger S, Wesseling P: RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations. Acta Neuropathol 2007, 114: 121-133. 10.1007/s00401-007-0239-0
7. Knobbe CB, Reifenberger J, Reifenberger G: Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol 2004, 108: 467-470. 10.1007/s00401-004-0929-9
8. Myung JK, Cho H, Park CK, Kim SK, Lee SH, Park SH: Analysis of the BRAF(V600E) Mutation in Central Nervous System Tumors. Transl Oncol 2012, 5: 430-436.
9. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, et al.: Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011, 121: 397-405. 10.1007/s00401-011-0802-6
10. Dougherty MJ, Santi M, Brose MS, Ma C, Resnick AC, Sievert AJ, Storm PB, Biegel JA: Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol 2010, 12: 621-630. 10.1093/neuonc/noq007
11. Forshew T, Tatevossian RG, Lawson AR, Ma J, Neale G, Ogunkolade BW, Jones TA, Aarum J, Dalton J, Bailey S, et al.: Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol 2009, 218: 172-181. 10.1002/path.2558
12. Lin A, Rodriguez FJ, Karajannis MA, Williams SC, Legault G, Zagzag D, Burger PC, Allen JC, Eberhart CG, Bar EE: BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants. J Neuropathol Exp Neurol 2012, 71: 66-72. 10.1097/NEN.0b013e31823f2cb0
13. Rodriguez FJ, Ligon AH, Horkayne-Szakaly I, Rushing EJ, Ligon KL, Vena N, Garcia DI, Cameron JD, Eberhart CG: BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper. J Neuropathol Exp Neurol 2012, 71: 789-794. 10.1097/NEN.0b013e3182656ef8
14. Dias-Santagata D, Lam Q, Vernovsky K, Vena N, Lennerz JK, Borger DR, Batchelor TT, Ligon KL, Iafrate AJ, Ligon AH, et al.: BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One 2011, 6: e17948. 10.1371/journal.pone.0017948
15. Koelsche C, Wöhrer A, Jeibmann A, Schittenhelm J, Schindler G, Preusser M, Lasitschka F, Deimling A, Capper D: Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathol 2013, 125: 891-900. 10.1007/s00401-013-1100-2
16. Chappe C, Padovani L, Scavarda D, Forest F, Nanni-Metellus I, Loundou A, Mercurio S, Fina F, Lena G, Colin C, Figarella-Branger D: Dysembryoplastic Neuroepithelial Tumors Share with Pleomorphic Xanthoastrocytomas and Gangliogliomas BRAF Mutation and Expression. Brain Pathol 2013. Epub ahead of print
17. Amanuel B, Grieu F, Kular J, Millward M, Iacopetta B: Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region. Pathology 2012, 44: 357-359. 10.1097/PAT.0b013e3283532565
18. Long GV, Wilmott JS, Capper D, Preusser M, Zhang YE, Thompson JF, Kefford RF, von Deimling A, Scolyer RA: Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol 2013, 37: 61-65. 10.1097/PAS.0b013e31826485c0
19. Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, Kefford RF, Scolyer RA, Long GV: Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 2012, 18: 3242-3249. 10.1158/1078-0432.CCR-12-0052
20. Skorokhod A, Capper D, von Deimling A, Enk A, Helmbold P: Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1. J Am Acad Dermatol 2012, 67: 488-491. 10.1016/j.jaad.2012.03.022
21. El-Osta H, Falchook G, Tsimberidou A, Hong D, Naing A, Kim K, Wen S, Janku F, Kurzrock R: BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS One 2011, 6: e25806. 10.1371/journal.pone.0025806
22. Bettegowda C, Agrawal N, Jiao Y, Wang Y, Wood LD, Rodriguez FJ, Hruban RH, Gallia GL, Binder ZA, Riggins CJ, et al.: Exomic Sequencing of Four Rare Central Nervous System Tumor Types. Oncotarget 2013, 4: 572-583.
23. Giannini C, Paulus W, Louis DN, Liberski P: Pleomorphic Xanthoastrocytoma in WHO Classification of Tumours of the Central Nervous System (IARC WHO Classification of Tumours). 1st edition. Lyon: ; 2007:22-24.
24. Giannini C, Scheithauer BW, Burger PC, Brat DJ, Wollan PC, Lach B, O'Neill BP: Pleomorphic xanthoastrocytoma: what do we really know about it? Cancer 1999, 85: 2033-2045.
25. Kleinschmidt-Demasters BK, Aisner DL, Birks DK, Foreman NK: Epithelioid GBMs Show a High Percentage of BRAF V600E Mutation. Am J Surg Pathol 2013, 37: 685-698. 10.1097/PAS.0b013e31827f9c5e
26. Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, Pusch S, Mechtersheimer G, Zentgraf H, von Deimling A: Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011, 122: 11-19. 10.1007/s00401-011-0841-z
27. Colomba E, Helias-Rodzewicz Z, Von Deimling A, Marin C, Terrones N, Pechaud D, Surel S, Cote JF, Peschaud F, Capper D, et al.: Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. J Mol Diagn 2013, 15: 94-100. 10.1016/j.jmoldx.2012.09.001
28. Feller JK, Yang S, Mahalingam M: Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma. Mod Pathol 2013, 26: 414-420. 10.1038/modpathol.2012.168
29. Bullock M, O'Neill C, Chou A, Clarkson A, Dodds T, Toon C, Sywak M, Sidhu SB, Delbridge LW, Robinson BG, et al.: Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma. Endocr Relat Cancer 2012, 19: 779-784. 10.1530/ERC-12-0239
30. Koperek O, Kornauth C, Capper D, Berghoff AS, Asari R, Niederle B, von Deimling A, Birner P, Preusser M: Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol 2012, 36: 844-850. 10.1097/PAS.0b013e318246b527
31. Andrulis M, Penzel R, Weichert W, von Deimling A, Capper D: Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol 2012, 36: 1796-1800. 10.1097/PAS.0b013e3182549b50
32. Bosmuller H, Fischer A, Pham DL, Fehm T, Capper D, von Deimling A, Bonzheim I, Staebler A, Fend F: Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. Hum Pathol 2013, 44: 329-335. 10.1016/j.humpath.2012.07.010
33. Ilie M, Long E, Hofman V, Dadone B, Marquette CH, Mouroux J, Vignaud JM, Begueret H, Merlio JP, Capper D, et al.: Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. Ann Oncol 2013, 24: 742-748. 10.1093/annonc/mds534
34. Capper D, Berghoff AS, Magerle M, Ilhan A, Wohrer A, Hackl M, Pichler J, Pusch S, Meyer J, Habel A, et al.: Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 2012, 123: 223-233. 10.1007/s00401-011-0887-y
35. Sperveslage J, Gierke M, Capper D, Honegger J, Sipos B, Beschorner R, Schittenhelm J: VE1 immunohistochemistry in pituitary adenomas is not associated with BRAF V600E mutation. Acta Neuropathol 2013, 125: 911-912. 10.1007/s00401-013-1118-5
36. Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics 1977, 33: 159-174. 10.2307/2529310
37. Fleiss JL, Levin B, Paik MC, Fleiss J: Statistical Methods for Rates & Proportions Third edn. New York: Wiley-Interscience; 2003.
38. Fleiss JL, Nee JC, Landis JR: Large sample variance of kappa in the case of different sets of raters. Psychol Bull 1979, 86: 974-977.
39. Kendall MG: Rank correlation methods. London: Charles Griffin & Co. Ltd.; 1955.